Blood test improves lung cancer screening accuracy

A blood-based cfDNA fragmentome assay for lung cancer detection showed 84% sensitivity, 58% specificity, and 99.8% NPV. With a 0.7% lung cancer prevalence, the NNS was 143. The assay could reduce lung cancer deaths by 14,264 in high adoption scenarios. It offers a cost-effective, accurate screening tool, potentially decreasing late-stage diagnoses and fatalities.